Drug intelligence / Profile preview

DeepCure TNFα inhibitor

Development stage: Preclinical
Lead developer: DeepCure
Modality: Small Molecules
Administration: Oral

Overview

DeepCure is developing an oral small molecule inhibitor of Tumor Necrosis Factor alpha (TNFα) for the treatment of various autoimmune indications. Developed using an AI-driven molecular discovery platform, this candidate is designed to provide a more convenient oral alternative to the injectable monoclonal antibodies (such as adalimumab or etanercept) that currently dominate the TNFα inhibitor market. By blocking the activity of TNFα, a key pro-inflammatory cytokine, the drug aims to modulate the systemic inflammatory response associated with autoimmune diseases. The program is currently in the late discovery/preclinical stage.

Other names: TNFα small molecule inhibitor

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on DeepCure TNFα inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DeepCure TNFα inhibitor.

Explore the full profile